GSK126 could effectively suppress proliferation of EZH2 mutant DLBCL cell lines and inhibit tumor growth in xenograft mouse model of EZH2 mutant DLBCL in vivo, indicating pharmacological inhibition of EZH2 activity may show promise in treating DLBCL harboring activating mutations of EZH2 [59]. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.